Darin Lippoldt, insider at Neurocrine Biosciences

Darin Lippoldt Insider Information

Darin M. Lippoldt J.D. serves as Chief Legal Officer and Corporate Secretary of the Company. He was appointed Chief Legal Officer and Corporate Secretary in October 2014 and has oversight of all corporate legal matters, intellectual property, and corporate compliance. Prior to joining Neurocrine Biosciences, Mr. Lippoldt served as Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations and a J.D. from St. Mary’s University.

What is Darin Lippoldt's net worth?

The estimated net worth of Darin Lippoldt is at least $2.94 million as of July 9th, 2020. Mr. Lippoldt owns 27,678 shares of Neurocrine Biosciences stock worth more than $2,936,913 as of August 17th. This net worth approximation does not reflect any other assets that Mr. Lippoldt may own. Learn More about Darin Lippoldt's net worth.

How old is Darin Lippoldt?

Mr. Lippoldt is currently 56 years old. There are 7 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 64 years old. Learn More on Darin Lippoldt's age.

How do I contact Darin Lippoldt?

The corporate mailing address for Mr. Lippoldt and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected] Learn More on Darin Lippoldt's contact information.

Has Darin Lippoldt been buying or selling shares of Neurocrine Biosciences?

Darin Lippoldt has not been actively trading shares of Neurocrine Biosciences over the course of the past ninety days. Most recently, Darin Lippoldt sold 8,455 shares of the business's stock in a transaction on Tuesday, March 22nd. The shares were sold at an average price of $95.05, for a transaction totalling $803,647.75. Learn More on Darin Lippoldt's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, insiders at the sold shares 17 times. They sold a total of 145,560 shares worth more than $13,063,417.10. The most recent insider tranaction occured on August, 12th when insider Malcolm Lloyd-Smith sold 21,533 shares worth more than $2,281,421.35. Insiders at Neurocrine Biosciences own 4.4 % of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 8/12/2022.

Darin Lippoldt Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2022Sell8,455$95.05$803,647.75View SEC Filing Icon  
3/18/2022Sell300$95.00$28,500.00View SEC Filing Icon  
7/9/2020Sell1,657$136.02$225,385.1427,678View SEC Filing Icon  
5/18/2020Sell5,000$120.00$600,000.0031,021View SEC Filing Icon  
11/8/2019Sell10,000$110.01$1,100,100.0026,728View SEC Filing Icon  
9/3/2019Sell6,736$100.00$673,600.00View SEC Filing Icon  
8/27/2019Sell3,264$100.05$326,563.2021,625View SEC Filing Icon  
8/23/2019Sell1,664$100.09$166,549.7621,625View SEC Filing Icon  
7/30/2019Sell15,831$92.13$1,458,510.03160,732View SEC Filing Icon  
1/3/2018Sell1,979$79.36$157,053.44View SEC Filing Icon  
12/28/2017Sell15,237$75.00$1,142,775.00View SEC Filing Icon  
12/28/2017Sell15,237$75.00$1,142,775.0028,394View SEC Filing Icon  
12/8/2017Sell2,955$75.00$221,625.0016,112View SEC Filing Icon  
12/4/2017Sell6,279$75.04$471,176.1619,436View SEC Filing Icon  
11/15/2017Sell9,900$73.05$723,195.00View SEC Filing Icon  
11/9/2015Sell23,761$52.92$1,257,432.12View SEC Filing Icon  
See Full Table

Darin Lippoldt Buying and Selling Activity at Neurocrine Biosciences

This chart shows Darin Lippoldt's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $106.11
Low: $104.31
High: $108.62

50 Day Range

MA: $97.04
Low: $88.93
High: $107.66

2 Week Range

Now: $106.11
Low: $71.88
High: $109.26


805,575 shs

Average Volume

788,892 shs

Market Capitalization

$10.15 billion

P/E Ratio


Dividend Yield